"Gene therapy has given me the ability to take full control of my life... in a world where the deck was stacked against me, gene therapy has been a winning hand" - Jimi Olaghere, one of the first patients in Vertex’s exa-cel trial. An interesting article published yesterday on this week's FDA expert advisory panel for exa-cel, covering discussions held by the panel on approaches by Vertex to quantify off-target risk, suggested further safety studies, and feedback from a handful of people who have received the therapy so far. The CRISPR 2.0 Congress (Nov 28-30, Boston) will be tackling head-on challenges with safety studies and off-target assessing/predicting/monitoring. Attendees will also have the chance to leverage 17 new data readouts and 16 new tech pieces from the likes of CRISPR Therapeutics, Editas Medicine, Caribou Biosciences, Beam Therapeutics, Prime Medicine, Inc., etc. 📣 You can save $500 if you register before the EOD Friday, Nov 3. Check out pricing options here: https://ter.li/ad72fn #CRISPR #GeneEditing #Conference https://lnkd.in/eHE-WmRk
CTO CRISPR Gene Editing
12moThanks for posting Nick Mayne. Excited to be part of the #CRIPSR 2.0 conference.